San Francisco-based Bone Health Technologies (BHT) has presented pivotal trial data for its novel treatment Osteoboost at the renowned endocrinology conference, Endo 2023. The double-blind study enrolled 126 postmenopausal women with low bone mass, focusing on the effectiveness of Osteoboost in reducing the decline of bone strength and density. The Osteoboost device, which is seeking FDA’s Class 2 Prescription De Novo Approval,…
